[ad_1]
British drugmaker AstraZeneca Plc informed Reuters on Tuesday that its COVID-19 vaccine ought to be efficient in opposition to the brand new coronavirus variant, including that research had been beneath strategy to totally probe the affect of the mutation.
“AZD1222 (AstraZeneca’s vaccine candidate) contains the genetic material of the SARS-CoV-2 virus spike protein, and the changes to the genetic code seen in this new viral strain do not appear to change the structure of the spike protein,” an AstraZeneca spokesperson stated in an e mail.
Disclaimer: This put up has been auto-published from an company feed with none modifications to the textual content and has not been reviewed by an editor
[ad_2]
Source hyperlink